Andrew Finn

This inventor holds 6 USPTO granted patents and 52 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignee: Biodelivery Sciences International, Inc.. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Finn. Retrieved from https://idiyas.com/inventor/andrew-finn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 52)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 76(Granted Patents)

Company Filing History:

6 out of 8

Biodelivery Sciences International, Inc.

patents

Years Active: 2012-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9901539 - Transmucosal drug delivery devices for use in chronic pain relief (2018-02-27),

2. 9655843 - Transmucosal delivery devices with enhanced uptake (2017-05-23),

3. 9597288 - Transmucosal delivery devices with enhanced uptake (2017-03-21),

4. 9522188 - Abuse resistant transmucosal drug delivery device (2016-12-20),

5. 8703177 - Abuse-resistant mucoadhesive devices for delivery of buprenorphine (2014-04-22),

6. 8147866 - Transmucosal delivery devices with enhanced uptake (2012-04-03),

Title: Innovations by Andrew Finn in Transmucosal Drug Delivery

Introduction

Andrew Finn is an accomplished inventor based in Raleigh, NC, with a focus on developing innovative drug delivery systems. He holds a total of six patents, showcasing his commitment to advancing medical technology and improving patient care.

Latest Patents

Among his latest patents, Finn has developed a transmucosal drug delivery device specifically designed for chronic pain relief. This device allows for the administration of low doses of buprenorphine either twice daily or once daily, effectively treating chronic pain while minimizing significant side effects. Another notable invention is a method for enhancing transmucosal uptake of medications such as fentanyl or buprenorphine. This invention includes devices that facilitate the transmucosal administration of these medicaments, utilizing a mucoadhesive polymeric diffusion environment and a barrier environment to optimize delivery.

Career Highlights

Finn is currently associated with BioDelivery Sciences International, Inc., where he continues to innovate in the field of drug delivery systems. His work has significantly contributed to the development of effective pain management solutions.

Collaborations

Finn collaborates with Niraj Vasisht, leveraging their combined expertise to further enhance the efficacy of their inventions.

Conclusion

Andrew Finn's contributions to the field of drug delivery through his innovative patents demonstrate his dedication to improving healthcare solutions. His work continues to pave the way for advancements in chronic pain management.

Profile summary based on public USPTO records.